This HTML5 document contains 21 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n5http://linked.opendata.cz/resource/mesh/concept/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n7http://linked.opendata.cz/resource/fda-spl/ingredient/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n4http://linked.opendata.cz/ontology/mesh/
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
n8http://linked.opendata.cz/resource/ndfrt/ingredient/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C47510
rdf:type
owl:Class
rdfs:label
Enalaprilat
rdfs:subClassOf
nci:C247
nci:A8
nci:C63923
nci:P106
Pharmacologic Substance
nci:P108
Enalaprilat
nci:P207
C0014027
nci:P210
84680-54-6
nci:P319
GV0O7ES0R3
nci:P322
FDA
nci:P350
C18H24N2O5.2H2O
nci:P366
Enalaprilat
nci:P368
CHEBI:59877
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Enalaprilat</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>N-(1(S)-Carboxy-3-phenylpropyl)-L-alanyl-L-proline</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ENALAPRILAT</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>GV0O7ES0R3</n0:source-code></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>The active metabolite of the pro-drug enalapril, a dicarboxylate-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Enalaprilat prevents the conversion of angiotensin I into angiotensin II by inhibiting ACE, thereby leading to decreased vasopressor activity and resulting in vasodilation. This agent also decreases aldosterone secretion by the adrenal cortex, which leads to an increase in natriuresis.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C47510
owl:sameAs
n7:GV0O7ES0R3 n8:N0000006494
n4:hasConcept
n5:M0024167